Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.53 |
| ▸ | NPY1R | P25929 | 8/20 | 0.53 |
| ▸ | NPY2R | P49146 | 5/20 | 0.53 |
| ▸ | TFPI | P10646 | 1/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19471703 | 0.96 | NPY4R (0.53) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL19471873 | 0.89 | TFPI (0.50) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL29442083 | 0.89 | NPY4R (0.65) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL19471834 | 0.88 | TFPI (0.52) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL19471880 | 0.86 | NMUR2 (0.50) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL29442111 | 0.85 | NPY4R (0.69) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL29442105 | 0.84 | TFPI (0.61) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL29434681 | 0.84 | NPY4R (0.67) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL29434605 | 0.83 | NPY4R (0.71) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL29442114 | 0.81 | NPY4R (0.73) | NPY4RNPY5RNPY1RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180371060-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2018-12-27 | — | — | US | claimed |
| US-10081668-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | NORTHWESTERN UNIVERSITY (US) | 2018-09-25 | — | — | US | claimed |
| WO-2017189715-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | NORTHWESTERN UNIVERSITY (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170305998-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | NORTHWESTERN UNIVERSITY (US) | 2017-10-26 | — | — | US | claimed |
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | NORTHWESTERN UNIVERSITY (US) | 2022-03-01 | — | — | US | disclosed |
| US-20180371060-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2018-12-27 | — | — | US | disclosed |
| US-10081668-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | NORTHWESTERN UNIVERSITY (US) | 2018-09-25 | — | — | US | disclosed |
| US-20170305998-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | NORTHWESTERN UNIVERSITY (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305998-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | VEGFA, LITAF, HDGF | NPY4R 2100/4885NPY5R 2183/4885NPY1R 1668/4885 |
| US-10081668-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | VEGFA, LITAF, FIBP | NPY4R 2058/4885NPY5R 2142/4885NPY1R 1616/4885 |
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | VEGFA, LITAF, FIBP | NPY4R 2058/4885NPY5R 2142/4885NPY1R 1616/4885 |
| US-20180371060-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | VEGFA, LITAF, HDGF | NPY4R 2100/4885NPY5R 2183/4885NPY1R 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.